AC Immune SA is at the forefront of developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases. The company utilizes two proprietary technology platforms, Morphomer® and SupraAntigen®, to create a diverse pipeline of diagnostic and therapeutic candidates. The Morphomer® platform focuses on small molecule chemistry and biological assays to identify compounds that target pathological protein aggregates in the central nervous system. This platform has facilitated the development of several promising candidates, including PET tracers for Tau and alpha-synuclein, which are critical for diagnosing and understanding neurodegenerative conditions. 

The SupraAntigen® platform, on the other hand, leverages advanced liposome technology to design both active and passive immunization candidates. This technology allows for the precise presentation of antigens to stimulate immune responses against misfolded proteins associated with neurodegeneration. Active immunotherapies developed through this platform, such as ACI-24, target specific toxic forms of amyloid beta, while passive immunization approaches focus on generating monoclonal antibodies to combat these pathological proteins. Together, these platforms enable AC Immune to pioneer precision medicine strategies aimed at diagnosing, treating, and ultimately preventing neurodegenerative diseases.

Switzerland

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

Central Nervous System (CNS)

Nervous System Diseases

AC Immune SA

Alzheimer's disease

Neurological disorder

The Tau-PET tracer PI-2620 was designed to specifically bind &nbsp;pathological forms of human Tau in Alzheimer’s disease and other &nbsp;Tauopathies. It crosses the blood brain barrier and has high &nbsp;selectivity, even during early disease stages. A major differentiator is &nbsp;its ability to bind to 4-repeat (4R) Tau isoforms extending its use to &nbsp;diseases driven by these Tau species.

PI-2620

Tau protein inhibitors

Semorinemab 

Crenezumab

Parkinson's disease

ACI-7104 is an optimized formulation of its clinically validated anti-a-syn predecessor vaccine. It generates a target-specific antibody response against pathological oligomeric a-syn to inhibit spreading and downstream neurodegeneration in early Parkinson’s disease. It produces a strong and boostable antibody response with evidence of target engagement and a signal of clinical efficacy.

ACI-7104.056

ACI-35.030 is a potent liposomal anti-pTau active investigational vaccine designed to elicit antibodies against phosphorylated pathological Tau protein, in order to reduce and facilitate the clearance of related Tau aggregates, slowing the progression of Tau-pathology and/or treating the underlying Tauopathy.

JNJ-2056 (prev. ACI-35.030 or JACI-35.054)

Down Syndrome

ACI-24 is a liposome vaccine designed to elicit an antibody response &nbsp;against aggregated Aβ peptides without concomitant pro-inflammatory T &nbsp;cell activation.

ACI-24.060 (anti-Abeta vaccine)

Frontotemporal dementia

ACI-19626, TDP-43 imaging diagnostic. Our Morphomer platform has delivered the first-in-class TDP-43 PET tracer, 18F-ACI-19626 entering the FiH evaluation in healthy volunteers and in patients with TDP-43 proteinopathies. ACI-19626 shows optimal binding potential in frontotemporal lobar degeneration (FTLD)-TDP brain tissue with no binding to physiological TDP-43, excellent selectivity over other aggregated proteins commonly present in neurodegenerative diseases and aging brain, excellent pharmacokinetic properties suitable for human brain imaging. This PET tracer is envisioned to enable early and differential diagnosis, improve the design and interpretation of clinical trials allowing for patient stratification, selection of optimal timing for therapeutic intervention and pharmacodynamic effect evaluation. This first-in-class molecule could have a high impact, opening new opportunities for therapeutic interventions in diseases with high unmet medical needs and huge societal burdens, such as ALS, FTD and AD

AC Immune SA

Company Details